
## Emily Hajjar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10082919/publications.pdf Version: 2024-02-01



ΕΜΠΛ ΗΛΠΑΡ

#	Article	IF	CITATIONS
1	Clinical consequences of polypharmacy in elderly. Expert Opinion on Drug Safety, 2014, 13, 57-65.	2.4	1,217
2	Polypharmacy in elderly patients. American Journal of Geriatric Pharmacotherapy, 2007, 5, 345-351.	3.0	967
3	Evaluation of a Pharmacist-Led Medication Assessment Used to Identify Prevalence of and Associations With Polypharmacy and Potentially Inappropriate Medication Use Among Ambulatory Senior Adults With Cancer. Journal of Clinical Oncology, 2015, 33, 1453-1459.	1.6	208
4	Unnecessary Drug Use in Frail Older People at Hospital Discharge. Journal of the American Geriatrics Society, 2005, 53, 1518-1523.	2.6	195
5	Adverse drug reaction risk factors in older outpatients. American Journal of Geriatric Pharmacotherapy, 2003, 1, 82-89.	3.0	144
6	Clinically important drug-disease interactions and their prevalence in older adults. Clinical Therapeutics, 2006, 28, 1133-1143.	2.5	108
7	Polypharmacy and health beliefs in older outpatients. American Journal of Geriatric Pharmacotherapy, 2007, 5, 317-323.	3.0	63
8	Update on drug-related problems in the elderly. American Journal of Geriatric Pharmacotherapy, 2003, 1, 38-43.	3.0	47
9	A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence of complementary and alternative medication (CAM) use among ambulatory senior adults with cancer. Journal of Geriatric Oncology, 2015, 6, 411-417.	1.0	40
10	Potential Drug—Disease Interactions in Frail, Hospitalized Elderly Veterans. Annals of Pharmacotherapy, 2005, 39, 412-417.	1.9	37
11	Implementing a pharmacist-led, individualized medication assessment and planning (iMAP) intervention to reduce medication related problems among older adults with cancer. Journal of Geriatric Oncology, 2017, 8, 296-302.	1.0	35
12	Comparing pharmacy practice faculty perceptions of first-year post-graduate residency (PGY1) selection criteria to those reported by PGY1 residency directors. Currents in Pharmacy Teaching and Learning, 2015, 7, 20-28.	1.0	18
13	Isn't It Time We Stop Counting the Number of Drugs to Define Polypharmacy in This New Era of Deprescribing and What Related Outcomes Should Be Measured?. Journal of the American Medical Directors Association, 2018, 19, 644-645.	2.5	8
14	Sequencing of Simulation and Clinic Experiences in an Introductory Pharmacy Practice Experience. American Journal of Pharmaceutical Education, 2015, 79, 120.	2.1	4
15	Antipsychotic agents. Side Effects of Drugs Annual, 2020, 42, 81-89.	0.6	1
16	A pharmacist-led medication assessment to identify prevalence and associations with potentially inappropriate medications (PIMs) in ambulatory senior adults with cancer Journal of Clinical Oncology, 2014, 32, e20516-e20516.	1.6	1
17	A Failure to Guide: Patient Experiences within a State-Run Cannabis Program in Pennsylvania, United States. Substance Use and Misuse, 2022, 57, 516-521.	1.4	1
18	Factors That Influence the Decision to Staff a Medical Information Booth at a Medical Meeting. Drug Information Journal, 2010, 44, 351-358.	0.5	0